Works by D'Amico, Ronald


Results: 43
    1

    A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV.

    Published in:
    Clinical Pharmacology in Drug Development, 2025, v. 14, n. 7, p. 528, doi. 10.1002/cpdd.1538
    By:
    • Han, Kelong;
    • Benn, Paul;
    • Sievers, Jörg;
    • Dorey, David;
    • Warwick‐Sanders, Michael;
    • Hareedy, Randa;
    • Harkness, Louise;
    • Leemereise, Claudia;
    • Offenbecker, Kjersten;
    • Donatti, Christina;
    • Brimhall, Darin B.;
    • Schwabe, Christian;
    • Boyle, Craig;
    • Hassman, Michael A.;
    • Knowles, Steve;
    • D'Amico, Ronald;
    • Spreen, William R.
    Publication type:
    Article
    2
    3
    4
    5

    Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study.

    Published in:
    AIDS & Behavior, 2025, v. 29, n. 1, p. 64, doi. 10.1007/s10461-024-04490-0
    By:
    • Mussini, Cristina;
    • Cazanave, Charles;
    • Adachi, Eisuke;
    • Eu, Beng;
    • Alonso, Marta Montero;
    • Crofoot, Gordon;
    • Chounta, Vasiliki;
    • Kolobova, Irina;
    • Sutton, Kenneth;
    • Sutherland-Phillips, Denise;
    • Urbaityte, Rimgaile;
    • Ehmann, Alice;
    • Scherzer, Jenny;
    • de los Rios, Patricia;
    • D'Amico, Ronald;
    • Spreen, William;
    • van Wyk, Jean
    Publication type:
    Article
    6
    7

    SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF.

    Published in:
    Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 78
    By:
    • Ramgopal, Moti N.;
    • Castagna, Antonella;
    • Cazanave, Charles;
    • Diaz Brito, Vicens;
    • Dretler, Robin;
    • Oka, Shinichi;
    • Osiyemi, Olayemi;
    • Sutton, Kenneth;
    • Sutherland-Phillips, Denise;
    • Berni, Alessandro;
    • Latham, Christine;
    • Zhang, Feifan;
    • D'Amico, Ronald;
    • Smith, Kimberly;
    • Van Wyk, Jean
    Publication type:
    Article
    8

    WEIGHT AND METABOLIC CHANGES WITH CABOTEGRAVIR+RILPIVIRINE LONG-ACTING OR BICTEGRAVIR.

    Published in:
    Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 59
    By:
    • Tan, Darrell H. S.;
    • Antinori, Andrea;
    • Eu, Beng;
    • Galindo, Maria José;
    • Kinder, Clifford;
    • Sweet, Donna;
    • Van Dam, Cornelius N.;
    • Sutton, Kenneth;
    • Sutherland-Phillips, Denise;
    • Berni, Alessandro;
    • Zhang, Feifan;
    • Spreen, William R.;
    • Garges, Harmony P.;
    • Patel, Parul;
    • D'Amico, Ronald
    Publication type:
    Article
    9

    Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.

    Published in:
    HIV Medicine, 2024, v. 25, n. 3, p. 381, doi. 10.1111/hiv.13588
    By:
    • Oka, Shinichi;
    • Holohan, Vicki;
    • Shirasaka, Takuma;
    • Choi, Jun Yong;
    • Kim, Yeon‐Sook;
    • Chamay, Nadine;
    • Patel, Parul;
    • Polli, Joseph W.;
    • Ford, Susan L.;
    • Crauwels, Herta;
    • Garside, Louise;
    • D'Amico, Ronald;
    • Latham, Christine;
    • van Solingen‐Ristea, Rodica;
    • Baugh, Bryan;
    • van Wyk, Jean
    Publication type:
    Article
    10

    Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials.

    Published in:
    HIV Medicine, 2023, v. 24, n. 5, p. 568, doi. 10.1111/hiv.13439
    By:
    • Patel, Parul;
    • Ford, Susan L.;
    • Baker, Mark;
    • Meyer, Claudia;
    • Garside, Louise;
    • D'Amico, Ronald;
    • Van Solingen‐Ristea, Rodica;
    • Crauwels, Herta;
    • Polli, Joseph W.;
    • Seal, Ciara;
    • Yagüe Muñoz, Itziar;
    • Thiagarajah, Shanker;
    • Birmingham, Eileen;
    • Spreen, William R.;
    • Baugh, Bryan;
    • van Wyk, Jean;
    • Vannappagari, Vani
    Publication type:
    Article
    11
    12
    13

    Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.

    Published in:
    Clinical Infectious Diseases, 2023, v. 77, n. 10, p. 1423, doi. 10.1093/cid/ciad370
    By:
    • Orkin, Chloe;
    • Schapiro, Jonathan M;
    • Perno, Carlo F;
    • Kuritzkes, Daniel R;
    • Patel, Parul;
    • DeMoor, Rebecca;
    • Dorey, David;
    • Wang, Yongwei;
    • Han, Kelong;
    • Eygen, Veerle Van;
    • Crauwels, Herta;
    • Ford, Susan L;
    • Latham, Christine L;
    • Clair, Marty St.;
    • Polli, Joseph W;
    • Vanveggel, Simon;
    • Vandermeulen, Kati;
    • D'Amico, Ronald;
    • Garges, Harmony P;
    • Zolopa, Andrew
    Publication type:
    Article
    14

    Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.

    Published in:
    Journal of Infectious Diseases, 2024, v. 230, n. 1, p. e34, doi. 10.1093/infdis/jiad580
    By:
    • Elliot, Emilie R;
    • Polli, Joseph W;
    • Patel, Parul;
    • Garside, Louise;
    • Grove, Richard;
    • Barnett, Vincent;
    • Roberts, Jeremy;
    • Byrapuneni, Sri;
    • Crauwels, Herta;
    • Ford, Susan L;
    • Solingen-Ristea, Rodica Van;
    • Birmingham, Eileen;
    • D'Amico, Ronald;
    • Baugh, Bryan;
    • Wyk, Jean van
    Publication type:
    Article
    15

    Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial.

    Published in:
    AIDS Patient Care & STDs, 2023, v. 37, n. 1, p. 53, doi. 10.1089/apc.2022.0168
    By:
    • Karver, Tahilin Sanchez;
    • Pascual-Bernaldez, Miguel;
    • Berni, Alessandro;
    • Hnoosh, Ahmed;
    • Castagna, Antonella;
    • Messiaen, Peter;
    • Puerto, Maria Jose Galindo;
    • Bloch, Mark;
    • Adachi, Eisuke;
    • Sinclair, Gary;
    • Felizarta, Franco;
    • Angel, Jonathan B.;
    • Sutton, Kenneth;
    • Sutherland-Phillips, Denise;
    • D'Amico, Ronald;
    • Kerrigan, Deanna
    Publication type:
    Article
    16
    17

    Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects.

    Published in:
    British Journal of Clinical Pharmacology, 2022, v. 88, n. 10, p. 4607, doi. 10.1111/bcp.15439
    By:
    • Han, Kelong;
    • Baker, Mark;
    • Lovern, Mark;
    • Paul, Prokash;
    • Xiong, Yuan;
    • Patel, Parul;
    • Moore, Katy P.;
    • Seal, Ciara S.;
    • Cutrell, Amy G.;
    • D'Amico, Ronald D.;
    • Benn, Paul D.;
    • Landovitz, Raphael J.;
    • Marzinke, Mark A.;
    • Spreen, William R.;
    • Ford, Susan L.
    Publication type:
    Article
    18
    19

    Multiparametric magnetic resonance imaging to characterize cabotegravir long‐acting formulation depot kinetics in healthy adult volunteers.

    Published in:
    British Journal of Clinical Pharmacology, 2022, v. 88, n. 4, p. 1655, doi. 10.1111/bcp.14977
    By:
    • Jucker, Beat M.;
    • Fuchs, Edward J.;
    • Lee, Sarah;
    • Damian, Valeriu;
    • Galette, Paul;
    • Janiczek, Robert;
    • Macura, Katarzyna J.;
    • Jacobs, Michael A.;
    • Weld, Ethel D.;
    • Solaiyappan, Meiyappan;
    • D'Amico, Ronald;
    • Shaik, Jafar Sadik;
    • Bakshi, Kalpana;
    • Han, Kelong;
    • Ford, Susan;
    • Margolis, David;
    • Spreen, William;
    • Gupta, Manish K.;
    • Hendrix, Craig W.;
    • Patel, Parul
    Publication type:
    Article
    20

    Long-Acting Cabotegravir+Rilpivirine Every 2 Months: ATLAS-2M Week 152 Results.

    Published in:
    Infection & Chemotherapy, 2022, v. 54, p. 276
    By:
    • Overton, Edgar T.;
    • Richmond, Gary;
    • Rizzardini, Giuliano;
    • Thalme, Anders;
    • Girard, Pierre-Marie;
    • Wong, Alexander;
    • Porteiro, Norma;
    • Espanol, Carlos Martin;
    • Acuipil, Carolina;
    • Aksar, Asma;
    • Wang, Yuanyuan;
    • D’Amico, Ronald;
    • Talarico, Christine;
    • Vandermeulen, Kati;
    • Spreen, William R.;
    • Yeon-Sook Kim
    Publication type:
    Article
    21
    22
    23

    Long-acting cabotegravir+rilpivirine every 2 months: ATLAS-2M week 152 results.

    Published in:
    Infection & Chemotherapy, 2022, v. 54, p. S310
    By:
    • Overton, Edgar T.;
    • Richmond, Gary;
    • Rizzardini, Giuliano;
    • Thalme, Anders;
    • Girard, Pierre-Marie;
    • Wong, Alexander;
    • Porteiro, Norma;
    • Martín Español, Carlos;
    • Acuipil, Carolina;
    • Aksar, Asma;
    • Yuanyuan Wang;
    • D’Amico, Ronald;
    • Talarico, Christine;
    • Vandermeulen, Kati;
    • Yeon-Sook Kim;
    • Spreen, William R.
    Publication type:
    Article
    24
    25
    26
    27
    28
    29

    Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration.

    Published in:
    Open Forum Infectious Diseases, 2024, v. 11, n. 6, p. 1, doi. 10.1093/ofid/ofae282
    By:
    • Teichner, Paula;
    • Chamay, Nadine;
    • Elliot, Emilie;
    • Pascual-Bernáldez, Miguel;
    • Merrill, Deanna;
    • Garris, Cindy;
    • D'Amico, Ronald;
    • Felizarta, Cecy;
    • Torres, Emma;
    • Solingen-Ristea, Rodica Van;
    • Baugh, Bryan;
    • Patel, Parul;
    • Vannappagari, Vani;
    • Dakhia, Samia;
    • Polli, Joseph W;
    • Garside, Louise;
    • Grove, Richard;
    • Thiagarajah, Shanker;
    • Birmingham, Eileen;
    • Wyk, Jean van
    Publication type:
    Article
    30
    31
    32

    884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies.

    Published in:
    Open Forum Infectious Diseases, 2019, v. 6, p. S20, doi. 10.1093/ofid/ofz359.043
    By:
    • Teichner, Paula;
    • Cutrell, Amy;
    • D'Amico, Ronald;
    • Dorey, David;
    • Griffith, Sandy;
    • Harrington, Conn M;
    • Huang, Jenny;
    • Hudson, Krischan J;
    • Margolis, David;
    • Mrus, Joseph;
    • Polli, Joseph;
    • Spreen, William;
    • Williams, Peter;
    • Solingen-Ristea, Rodica Van;
    • Shaefer, Mark S
    Publication type:
    Article
    33

    Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.

    Published in:
    Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19500
    By:
    • Eron, Joseph J;
    • Lalezari, Jay;
    • Slim, Jihad;
    • Gathe, Joseph;
    • Ruane, Peter J;
    • Wang, Chia;
    • Elion, Richard;
    • Blick, Gary;
    • Khatri, Amit;
    • Hu, Yiran B;
    • Gibbons, Krystal;
    • Fredrick, Linda;
    • Co, Melannie;
    • D'Amico, Ronald;
    • Da Silva-Tillmann, Barbara;
    • Trinh, Roger;
    • Sulkowski, Mark S
    Publication type:
    Article
    34

    The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment.

    Published in:
    PLoS ONE, 2012, v. 7, n. 4, p. 1, doi. 10.1371/journal.pone.0034399
    By:
    • Skinner-Adams, Tina S.;
    • Butterworth, Alice S.;
    • Porter, Kimberly A.;
    • D'Amico, Ronald;
    • Sawe, Fred;
    • Shaffer, Doug;
    • Siika, Abraham;
    • Hosseinipour, Mina C.;
    • Stringer, Elizabeth;
    • Currier, Judith S.;
    • Chipato, Tsungai;
    • Salata, Robert;
    • Lockman, Shahin;
    • Eron, Joseph J.;
    • Meshnick, Steven R.;
    • McCarthy, James S.
    Publication type:
    Article
    35

    CARISEL Çalışmasının Bir Etkililik ve Güvenlilik Alt Grup Analizi.

    Published in:
    Mediterranean Journal of Infection, Microbes & Antimicrobials, 2024, v. 13, p. 105
    By:
    • Ghosn, Jade;
    • Hocqueloux, Laurent;
    • Canales, María José Crusells;
    • Belkhir, Leïla;
    • Oldenbüttel, Celia Jonsson;
    • Lutz, Thomas;
    • Van Der Valk, Marc;
    • Van Welzen, Berend J.;
    • Hove, Kai;
    • Khaled, Mounir Ait;
    • Demoor, Rebecca;
    • Bontempo, Gilda;
    • Latham, Christine L.;
    • Gutner, Cassidy A.;
    • Iyer, Supriya;
    • Gill, Martin;
    • D'amico, Ronald;
    • Van Wyk, Jean;
    • Czarnogorski, Maggie;
    • İnce, İrem
    Publication type:
    Article
    36

    İki Ayda Bir Enjektabl Uzun Etkili Cabotegravir + Rilpivirin (CAB + RPV) Tedavi Rejimi: ATLAS-2M Çalışması 152. Hafta Sonuçları.

    Published in:
    Mediterranean Journal of Infection, Microbes & Antimicrobials, 2022, v. 11, p. 129
    By:
    • Overton, Edgar T.;
    • Richmond, Gary;
    • Rizzardini, Giuliano;
    • Thalme, Anders;
    • Girard, Pierre Marie;
    • Wong, Alexander;
    • Porteiro, Norma;
    • Español, Carlos Martín;
    • Acuipil, Carolina;
    • Aksar, Asma;
    • Yuanyuan Wang;
    • D’amico, Ronald;
    • Talarico, Christine;
    • Vandermeulen, Kati;
    • Spreen, William R.;
    • Paracıklı, Gürcan
    Publication type:
    Article
    37
    38
    39
    40
    41

    Implementation of long‐acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.

    Published in:
    Journal of the International AIDS Society, 2024, v. 27, n. 7, p. 1, doi. 10.1002/jia2.26243
    By:
    • Gutner, Cassidy A.;
    • Hocqueloux, Laurent;
    • Jonsson‐Oldenbüttel, Celia;
    • Vandekerckhove, Linos;
    • van Welzen, Berend J.;
    • Slama, Laurence;
    • Crusells‐Canales, María;
    • Sierra, Julián Olalla;
    • DeMoor, Rebecca;
    • Scherzer, Jenny;
    • Ait‐Khaled, Mounir;
    • Bontempo, Gilda;
    • Gill, Martin;
    • Patel, Natasha;
    • D'Amico, Ronald;
    • Hove, Kai;
    • Baugh, Bryan;
    • Barnes, Nicola;
    • Hadi, Monica;
    • Low, Emma L.
    Publication type:
    Article
    42

    Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation‐effectiveness study.

    Published in:
    Journal of the International AIDS Society, 2022, v. 25, n. 9, p. 1, doi. 10.1002/jia2.26006
    By:
    • Garris, Cindy P.;
    • Czarnogorski, Maggie;
    • Dalessandro, Marybeth;
    • D'Amico, Ronald;
    • Nwafor, Toyin;
    • Williams, Will;
    • Merrill, Deanna;
    • Wang, YuanYuan;
    • Stassek, Larissa;
    • Wohlfeiler, Michael B.;
    • Sinclair, Gary I.;
    • Mena, Leandro A.;
    • Thedinger, Blair;
    • Flamm, Jason A.;
    • Benson, Paul;
    • Spreen, William R.
    Publication type:
    Article
    43

    Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE).

    Published in:
    Journal of the International AIDS Society, 2022, v. 25, n. 9, p. 1, doi. 10.1002/jia2.26003
    By:
    • Czarnogorski, Maggie;
    • Garris, Cindy P.;
    • Dalessandro, Marybeth;
    • D'Amico, Ronald;
    • Nwafor, Toyin;
    • Williams, Will;
    • Merrill, Deanna;
    • Wang, YuanYuan;
    • Stassek, Larissa;
    • Wohlfeiler, Michael B.;
    • Sinclair, Gary I.;
    • Mena, Leandro A.;
    • Thedinger, Blair;
    • Flamm, Jason A.;
    • Benson, Paul;
    • Spreen, William R.
    Publication type:
    Article